BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24551032)

  • 1. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.
    Chattopadhyay C; Grimm EA; Woodman SE
    PLoS One; 2014; 9(2):e83957. PubMed ID: 24551032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
    Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
    Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
    Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.
    Radtke S; Milanovic M; Rossé C; De Rycker M; Lachmann S; Hibbert A; Kermorgant S; Parker PJ
    J Cell Sci; 2013 Jun; 126(Pt 11):2381-91. PubMed ID: 23549785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MET oncogene inhibition as a potential target of therapy for uveal melanomas.
    Abdel-Rahman MH; Boru G; Massengill J; Salem MM; Davidorf FH
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3333-9. PubMed ID: 20164465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
    Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
    Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
    Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
    Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
    Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.
    Garon EB; Finn RS; Hosmer W; Dering J; Ginther C; Adhami S; Kamranpour N; Pitts S; Desai A; Elashoff D; French T; Smith P; Slamon DJ
    Mol Cancer Ther; 2010 Jul; 9(7):1985-94. PubMed ID: 20587667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
    Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
    Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.